- Latest available (Revised)
- Point in Time (01/04/2010)
- Original (As made)
Version Superseded: 01/04/2012
Point in time view as at 01/04/2010.
There are currently no known outstanding effects for the The Medicines (Products for Human Use) (Fees) Regulations 2010 (revoked).
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
(This note is not part of the Regulations)
These Regulations revoke and re-enact in consolidated form, with some amendments, the Medicines (Products for Human Use) (Fees) Regulations 2009 (“the 2009 Regulations”) as amended by the Medicines (Products for Human Use) (Amendments relating to Fees for Variations) Regulations 2009. They make amendments to the Medicines (Homoeopathic Medicinal Products for Human Use) Regulations 1994 (“the 1994 Regulations”) and Medicines for Human Use (Clinical Trials) Regulations 2004 (“the Clinical Trials Regulations”).
These Regulations make provision for the fees payable under the Medicines Act 1971 and other fees payable in respect of EU obligations relating to marketing authorizations, licences and certificates in respect of medicinal products for human use.
The fees prescribed in the Regulations are revised on an annual basis following consultation and are based on an assessment of the costs associated with the functions in association with which fees are charged. The fees prescribed in the Regulations are set in line with a consultation document issued by the Medicines and Healthcare products Regulatory Agency (“MHRA”) on 19th October 2009. A summary of the consultation responses is published on the MHRA's website (www.mhra.gov.uk).
In general the overall average rate of increase of fees is approximately 1%, although in some cases individual fees will no longer be payable or new fees have been introduced.
Parts 2 to 9 and 11 and 12 and Schedules 1 and 2 provide for capital fees to be payable in connection with pre-application meetings; applications for, or variations to, marketing authorizations, manufacturer's licences, wholesale dealer's licences, clinical trial authorisations, traditional herbal registrations and certificates permitting the export of medicinal products; assistance in obtaining or renewing marketing authorizations in other EEA States; the assessment of labels and leaflets; renewals of certain manufacturer's licences; and inspections. Most of the fees were previously provided for by the 2009 Regulations (as amended).
However, these Regulations also introduce—
a new category of fee in connection with an application for a marketing authorization for a simple application which is a decentralised procedure where the UK is a reference Member State (entry 4(b) in the table in paragraph 24 of Schedule 1); and
two new categories of fee for an inspection comprising an office-based evaluation and risk assessment of documentation in relation to good manufacturing practice, good clinical practice, good pharmacovigilance practice or good distribution practice (regulation 27 and paragraph 8 of Schedule 2).
Part 10 and Schedule 3 to these Regulations impose periodic fees to be payable in connection with the holding of marketing authorizations, manufacturer's licences, registrations, authorisations and wholesale dealer's licences. The amount of the periodic fees varies according to the type of product and in some cases according to turnover.
Administrative provisions (Part 13, Schedules 4, 5 and 6) deal with time for payment and waiver or refund of both capital and periodic fees in specified circumstances. Special arrangements are provided in relation to the time of payment of capital fees by small companies.
Part 14 of these Regulations make amendments to increase fees specified in regulations 14 and 15 and Schedules 2 and 2A of the 1994 Regulations.
Part 15 of these Regulations makes consequential amendments to the Clinical Trials Regulations to provide for up to date cross-references to these Regulations.
Part 16 of these Regulations revokes earlier Regulations relating to fees for medicinal products for human use and also makes saving provisions.
An impact assessment of the effect that this instrument will have on the costs of business is available from the MHRA at Market Towers, 1 Nine Elms Lane, London SW8 5NQ.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: